Vishva Dixit

Vishva Mitra Dixit (born ) is a Kenyan-born American physician, biomedical researcher, and biotechnology executive whose discoveries transformed the modern understanding of programmed cell death, innate immunity, and inflammatory signaling. He is Vice President of Early Discovery Research at Genentech and is internationally recognized for elucidating the molecular mechanisms of apoptosis, identifying the signaling pathways of death receptors, discovering critical components of the caspase cascade, and pioneering research on inflammasomes, pyroptosis, necroptosis, and inflammatory cell death. His work has reshaped molecular and cellular biology and has had far-reaching implications for cancer biology, immunology, infectious diseases, neurodegeneration, and drug discovery.

Dixit has authored more than 300 scientific publications, many of which focuses on molecular biology and immunology. His discoveries established entirely new paradigms for understanding how cells undergo programmed death and how the innate immune system detects pathogens and tissue injury. Among his contributions are the identification of caspase-3 and caspase-8 as central regulators of apoptosis, elucidation of death receptor signaling through adaptor proteins and protease cascades, discovery of the noncanonical inflammasome pathway mediated by caspase-11, identification of Gasdermin D as the molecular executor of pyroptosis, characterization of RHIM-mediated signaling in necroptosis, and the demonstration that NINJ1 controls plasma membrane rupture during inflammatory cell death.

He has received awards including the Vilcek Prize in Biomedical Science , the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the Dr. A.H. Heineken Prize for Medicine, the Dawson Prize in Genetics , the Clowes Award of the American Association for Cancer Research, and the Gutenberg Prize.

He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and a foreign member of The Royal Society. His honours include the Dr. A.H. Heineken Prize for Medicine, the Vilcek Prize, the William B. Coley Award, and the Gutenberg Research Award. In 2026, he was elected to the American Philosophical Society.

Early life and education Vishva Dixit was born in Kenya in 1956. His parents were both physicians, working for the British colonial authorities. He graduated in 1980 from the University of Nairobi with a Bachelor of Medicine and Bachelor of Surgery, becoming a medical doctor.

Career

Academia After earning his M.D. from the University of Nairobi in 1981, Dixit moved to the United States for postgraduate training in laboratory medicine and pathology at Washington University School of Medicine. As of 2016 he held the position of Vice President of Discovery Research, His lab's discovery of MYD88 (25) as a central conduit for signals emanating from the interleukin-1 receptor is considered as one of the "Pillars in Immunology" by the Journal of Immunology.

Dixit's papers, including his work on apoptosis and inflammation, have been designated "hot papers" on multiple occasions by The Scientist. His research on apoptosis (programmed cell death) is now commonly found in introductory textbooks in both biology and medicine.

Early research on thrombospondin While at the University of Michigan, he received funding from the National Institutes of Health to support research into thrombospondin, as his laboratory had shown this protein had a role in promoting cancer metastases.

In 1996, he published the first evidence that death receptors engaged a mammalian deathase, a molecular scissors (protease) that cleaves proteins. His team's work on death receptor-induced apoptosis was notable, for prior to that time, cell surface receptors were thought to signal by functioning as ion channels or altering intracellular phosphorylation. Death receptors, however, signal by a different mechanism—activation of a death protease.

Collaborating with Guy Salvesen's group at the Burnham Institute, Dixit's group proposed the model of proximity-induced autoactivation in 1998 to explain how the first proteolytic signal is generated by caspase precursors recruited to death receptors.

RIP kinases, NF-κB signaling and necroptosis At Genentech, Dixit formed a team with the goal of unraveling the complex interplay between cell death and inflammation at the molecular level.

In 1999, his team discovered RIPK2 and RIPK3, which later were shown to be key mediators of NF-κB signaling and necroptosis, respectively. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, and improper immune development.

Dixit's work contributed to the discovery of a core complex composed of three proteins that enabled antigen receptors to activate the canonical NF-κB pathway: CARD11, BCL10 and MALT1/paracaspase. Furthermore, he postulated a protease activity for MALT1, which plays a role in T cell activation and MALT lymphomas.

In a series of papers between 2016 and 2020, Dixit and his colleagues at Genentech also worked out the complex molecular mechanisms that regulate activity of caspase-8, OTULIN, RIPK1, RIPK3 and other proteins that modulate inflammation, apoptosis and necroptosis signaling by death receptors and TLRs.

Inflammasomes and pyroptosis By 2002, Dixit was among the first scientists to demonstrate that pro-inflammatory caspases are part of a molecular complex named inflammasomes that are integral to the proper functioning of the innate immune system. In particular, he defined regulatory components upstream of caspase-1 that proteolytically activate the pro-inflammatory cytokines interleukin-1beta and interleukin-18.

More specifically, the intracellular protein NLRC4 was identified as a sensor for Salmonella that triggered assembly of an inflammasome complex. Derived analogs of this sulfonylurea class of compounds are currently in clinical development for inflammatory and neurodegenerative diseases.

Dixit's team discovered the non-canonical inflammasome pathway and its critical role in mediating lethal systemic inflammation in response to Gram-negative pathogens, detailed in three papers in 2011, 2013, and 2015.

The 2011 paper showed that mice lacking the gene that encodes caspase-1 also carry a mutation in a neighboring caspase gene, caspase-11 (caspase-4 in humans), which is responsible for many of the effects previously attributed to caspase-1, including sensitivity to sepsis.

The 2013 paper clarified the role of Toll-like receptor 4 and caspase-11 in inducing innate immune responses to Lipopolysaccharides (LPS), a cell wall component of Gram-negative bacteria. The research showed that recognition of intracellular LPS by innate immune cells leads to a form of necrotic, proinflammatory death, termed pyroptosis. They showed that these mechanisms did not depend on TLR4, but were rather mediated by caspase-11. This was significant, because for years it was assumed that TLR4 was solely responsible for cellular responses to LPS.

In the 2015 paper, they used mice subjected to random mutation to find mediators of caspase-11-dependent non-canonical inflammasome signaling. This led to the discovery that caspase-mediated cleavage of the protein GSDMD creates a pore forming, plasma membrane disrupting amino-terminal fragment that induces pyroptosis. The advances contributed to firmly establishing the sequence of events leading from inflammasome activation to pyroptosis, DAMP release, and lethal septic shock.

Using a similar research strategy, in 2021, they reported NINJ1 to be a mediator of plasma membrane rupture and DAMP release from pyroptotic cells.

Ubiquitin signaling (A20, LUBAC, OTULIN) In 1990, Dixit's lab at the University of Michigan discovered tumor necrosis factor (TNF)-inducible genes in endothelial cells, including A20/TNFAIP3. In later years, A20/TNFAIP3 would also achieve prominence as a modulator of inflammation.

In 2004, Dixit's group at Genentech discovered "ubiquitin editing" as a damping mechanism that attaches ubiquitin tags to TNF-receptor associated proteins to switch off pro-inflammatory signaling.

In 2018, in a similar vein, his group showed that the ubiquitin-cleaving enzyme, OTULIN, regulates cell death and inflammation by removing inhibitory linear ubiquitin chains from LUBAC, an enzyme that activates NF-κB.

They demonstrated that cleavage of Gasdermin D releases an amino-terminal fragment capable of oligomerizing within the plasma membrane to form large pores. These pores rapidly disrupt ionic homeostasis, leading to membrane rupture, inflammatory mediator release, and a specialized form of programmed inflammatory cell death known as pyroptosis.

Recent works One of his most recent discoveries was the identification of NINJ1 (Ninjurin-1) as the protein responsible for plasma membrane rupture during inflammatory cell death. Until this work, membrane rupture had generally been regarded as a passive consequence of osmotic swelling. In a 2021 study published in Nature, Dixit and colleagues demonstrated that NINJ1 actively oligomerizes within the plasma membrane to mediate its catastrophic rupture following activation of pyroptotic, apoptotic, and necrotic pathways. The discovery overturned a long-standing assumption in cell biology by establishing membrane rupture as a genetically regulated event rather than a passive biophysical process.

Building upon this work, his laboratory subsequently developed monoclonal antibodies capable of inhibiting NINJ1 oligomerization, demonstrating that pharmacological blockade of membrane rupture could significantly reduce tissue injury and inflammation in experimental disease models. These findings suggest that NINJ1 may represent a promising therapeutic target for inflammatory disorders, liver disease, infectious diseases, and conditions characterized by excessive cell death.

Dixit's group has also continued to investigate the molecular mechanisms regulating necroptosis and inflammatory signaling. Through genetic and biochemical studies, his laboratory elucidated how RHIM-containing proteins including RIPK1, RIPK3, ZBP1, and TRIF assemble signaling complexes that determine cellular responses to viral infection and inflammatory stress. These studies demonstrated remarkable plasticity among apoptosis, pyroptosis, and necroptosis pathways, revealing that inhibition of one pathway frequently results in compensatory activation of another.

Awards and honors

Dixit is an elected member of the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences.

In 2016, Dixit received the Gutenberg Research Award in Mainz, Germany. He also received the G.H.A. Clowes Memorial Award from the American Association for Cancer Research and the Dawson Prize in Genetics from Trinity College Dublin.

In 2017, he was elected Fellow of the American Association for Cancer Research. That same year, he participated in the Harvey Lecture Series, held by the Harvey Society at The Rockefeller University in New York City.

In 2018, Dixit received the Cell Death & Differentiation (CDD) Jurg Tschopp Prize at Clare College in Cambridge, United Kingdom. He has served on the boards of the Bill & Melinda Gates Foundation, Howard Hughes Medical Institute, and the Keystone Symposia on Molecular and Cellular Biology.

In 2022, Dixit received the Vilcek Prize in Biomedical Science, which honors outstanding immigrant scientists for their research leadership in the United States and is awarded by the Vilcek Foundation, the Dr. A.H. Heineken Prize for Medicine for his fundamental contributions to the fields of cell death and inflammation, and the Bijvoet Medal of the Bijvoet Centre for Biomolecular Research of Utrecht University. He also received the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology in 2022.

Selected publications